Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Clinical trial NCT06192797 · RECRUITING

Trial details

NCT number: NCT06192797
Sponsor: Tongji Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Cholangiocarcinoma Non-resectable

Start date: 2024-06-04
Primary completion: 2028-06-30
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.